Clinical Trial Update: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating amcenestrant plus palbociclib as first-line therapy for ER-positive, HER2-negative advanced breast cancer was terminated. Results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Amcenestrant (SAR439859)
• Palbociclib (palbociclib)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2023-07-06